MOLECULAR TUMOR BOARD

The UK Markey Cancer Center Molecular Tumor Board (MTB) is a forum of expert clinicians and scientists that discusses and analyzes tumor genotypes and molecular abnormalities in order to recommend patient-specific targeted therapies.

- Meetings occur every first and third Tuesday at noon Eastern Time in Markey’s Ben Roach Building, Room CC457, on the UK HealthCare campus in Lexington.
- Referrals are available to any physician within Kentucky and surrounding states.
- There is no cost for MTB review, but patients or their health insurance companies are responsible for costs associated with DNA sequencing and treatment medications.
- Healthcare professionals can participate in person or via teleconference. CE credit is available.
- MTB carefully balances emerging evidence and the clinical situation to offer customized recommendations. MTB will track patient outcomes through research studies.
- Review is limited to patients who have active, incurable cancer or rare cancers and who also have next-generation sequencing results.
- Patients whose cases are reviewed by MTB and subsequently enrolled in an observational cohort may count toward your facility’s clinical trial accrual for Commission on Cancer Standard 1.9.

To submit a case or for more information, contact Marissa Schuh, MTB Manager, at 1-844-622-0341 or mtb@uky.edu.